SOLICITATION NOTICE
A -- DNA Methylation & Genome Wide Association assays for evaluating changes in Epigenetic Aging for Veterans with HIV who participated in a Telehealth-delivered High-Intensity Exercise Program
- Notice Date
- 9/26/2024 9:16:31 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- RPO EAST (36C24E) PITTSBURGH PA 15212 USA
- ZIP Code
- 15212
- Solicitation Number
- 36C24E24Q0139
- Response Due
- 9/27/2024 6:00:00 AM
- Archive Date
- 10/02/2024
- Point of Contact
- Karly Gabrysiak, Contract Specialist, Phone: E-Mail only
- E-Mail Address
-
Karly.gabrysiak@va.gov
(Karly.gabrysiak@va.gov)
- Awardee
- null
- Description
- Amendment 1 Answer Vendor Questions for Solicitation 36C24E24Q0139. Question 1: We are performing independent research on the Combined Synopsis/Solicitation (36C24E24Q0139). We would like to know if this is a brand new contract OR if there is (was) an incumbent performing these services. If not brand new, could you please provide the current / previous contract number? Appreciate any insight you can provide. Answer to Question 1: This is new and there is no incumbent performing these services for the Requesting Activity for VA Portland Health Care System. Questions 2-8 were sent in together* Question 2: We utilize a custom EPIC V2 array with additional information. Would that array be appropriate to use for this project or would the standard EPIC V2 array be more appropriate? Answer to Question 2: The standard version of EPIC V2 array is what is planned for use. Question 3: Are the 102 samples to be used for GWAS a subset of the 191 or a separate cohort? In either case, can you help me better understand the expectation for sample processing in Item Number 4? Answer to Question 3: The 102 is a subset of the 191. The sample processing is any required processing to do the required assays only. Question 4: Is there an expectation to use genotyping arrays for the GWAS? If so, is there a preference or would one of the arrays we use for MVP be appropriate? Answer to Question 4: The GWAS array genotyping is part of the study. The MVP array is fine, as well as the Illumina GSA array. Question 5: Would PacBio long read sequencing be considered for the GWAS? Answer to Question 5: No, only the GWAS array for genotyping. See (3) above. Question 6: What should be the disposition of the samples once the assays are finished? Answer to Question 6: If possible, would be best to return to us. Question 7: Is there an expectation for data analysis beyond providing the raw data? Answer to Question 7: No data analysis needed. Question 8: What are the requirements for data delivery? Answer Question 8: Encrypted and sent via secure FTP. Upon award this will be facilitated.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/647c45933e9e403b989b3f9042c2952a/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN07225977-F 20240928/240926230116 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |